Abstract:ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of CancerJ. Jean Cui*, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish, Hong Shen, Lei Jia, Hengmiao Cheng, Jacqui Hoffman, Phuong Le, Mehran Jalaie, Gilles H. Goetz, Marcel Koenig, Tomas Vojkovsky, Fang-Jie Zhang, Steven Do, Iriny Botrous, Kevin Ryan, Neil Grodsky, Ya-li Deng, Max Parker, Sergei Timofeevski, Brion W. Murray, Shinji Yamazaki, Shirley Aguirre, Qiuhua Li, Helen Zou, and James ChristensenCite this: J. Med. Chem. 2012, 55, 22, 10314Publication Date (Web):October 19, 2012Publication History Published online19 October 2012Published inissue 26 November 2012https://pubs.acs.org/doi/10.1021/jm3014647https://doi.org/10.1021/jm3014647correctionACS PublicationsCopyright © 2012 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views1234Altmetric-Citations2LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (123 KB) Get e-Alertsclose Get e-Alerts

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Targeted Inhibition Of Stat/Tet1 Axis As A Therapeutic Strategy For Acute Myeloid Leukemia (Vol 8, 2017)

Pp2a Inhibition From Lb100 Therapy Enhances Daunorubicin Cytotoxicity In Secondary Acute Myeloid Leukemia Via Mir-181b-1 Upregulation (Vol 7, 2894, 2017)

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP

Correction to “discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3”

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead"

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Correction to "Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma"

Correction to "Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents"

Correction to "Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects"

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)